A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

NAEnrolling by invitationINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

Yishen Qutong Granules

The patent prescription of Professor Feng Li, the head of the Department of Traditional Chinese Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences.

DRUG

Yishen Qutong Simulant Granules

Yishen Qutong Simulant Granules is a preparation with one-tenth the dosage of Yishen Qutong Granules.

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Shaanxi Provincial Cancer Hospital

OTHER

collaborator

Changzhi People's Hospital

OTHER

collaborator

Yuncheng Central Hospital

OTHER

collaborator

Jilin Provincial Tumor Hospital

OTHER

collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Shanghai Chest Hospital

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Wuhan No.1 Hospital

OTHER

collaborator

Anyang Tumor Hospital

OTHER

collaborator

Chongqing University Cancer Hospital

OTHER

collaborator

Mianyang Central Hospital

OTHER

collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

collaborator

The First Hospital of Jilin University

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER